HK1126119A1 - Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13- - Google Patents

Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13-

Info

Publication number
HK1126119A1
HK1126119A1 HK09104420A HK09104420A HK1126119A1 HK 1126119 A1 HK1126119 A1 HK 1126119A1 HK 09104420 A HK09104420 A HK 09104420A HK 09104420 A HK09104420 A HK 09104420A HK 1126119 A1 HK1126119 A1 HK 1126119A1
Authority
HK
Hong Kong
Prior art keywords
inflammatory bowel
bowel disease
propanaediol
medicines
derivative
Prior art date
Application number
HK09104420A
Other languages
English (en)
Chinese (zh)
Inventor
小島僚太郎
中丸幸
安江德太郎
Original Assignee
杏林制藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1126119(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 杏林制藥株式會社 filed Critical 杏林制藥株式會社
Publication of HK1126119A1 publication Critical patent/HK1126119A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK09104420A 2006-02-06 2009-05-14 Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13- HK1126119A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006027883 2006-02-06
PCT/JP2007/051887 WO2007091501A1 (ja) 2006-02-06 2007-02-05 ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする炎症性腸疾患治療剤又は炎症性腸疾患の治療方法

Publications (1)

Publication Number Publication Date
HK1126119A1 true HK1126119A1 (en) 2009-08-28

Family

ID=38345101

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09104420A HK1126119A1 (en) 2006-02-06 2009-05-14 Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13-

Country Status (30)

Country Link
US (1) US8318811B2 (pt)
EP (2) EP2520291A1 (pt)
JP (1) JP5042042B2 (pt)
KR (1) KR101334153B1 (pt)
CN (1) CN101378743B (pt)
AU (1) AU2007213194B9 (pt)
BR (1) BRPI0706971A2 (pt)
CA (1) CA2641546C (pt)
CY (1) CY1116112T1 (pt)
DK (1) DK1982708T3 (pt)
EC (1) ECSP088662A (pt)
ES (1) ES2524056T3 (pt)
GT (1) GT200800148A (pt)
HK (1) HK1126119A1 (pt)
HR (1) HRP20080421B1 (pt)
IL (1) IL192150A (pt)
MA (1) MA31338B1 (pt)
MX (1) MX2008008872A (pt)
MY (1) MY151193A (pt)
NO (1) NO20082708L (pt)
NZ (1) NZ568907A (pt)
PL (1) PL1982708T3 (pt)
PT (1) PT1982708E (pt)
RU (1) RU2428976C2 (pt)
SG (1) SG169370A1 (pt)
SI (1) SI1982708T1 (pt)
TN (1) TNSN08246A1 (pt)
TW (1) TWI389683B (pt)
WO (1) WO2007091501A1 (pt)
ZA (1) ZA200806199B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101178318B1 (ko) 2004-07-16 2012-08-29 교린 세이야꾸 가부시키 가이샤 효과적인 의약의 사용법 및 부작용 발현의 방어에 관한방법
PL2511262T3 (pl) 2004-10-12 2017-08-31 Kyorin Pharmaceutical Co., Ltd. Sposób wytwarzania chlorowodorku 2-amino-2-[2-[4-(3-benzyloksyfenylotio)-2-chlorofenylo]etylo]-1,3-propanodiolu
BRPI0617077A2 (pt) 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
SG174029A1 (en) 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
KR101339976B1 (ko) 2006-08-08 2013-12-10 교린 세이야꾸 가부시키 가이샤 아미노인산에스테르 유도체 및 그들을 유효성분으로 하는 ｓ1ｐ 수용체 조절제
WO2009099174A1 (ja) * 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
KR20110010638A (ko) * 2008-05-20 2011-02-01 교린 세이야꾸 가부시키 가이샤 관해 도입 유지제
KR20170044760A (ko) * 2008-07-23 2017-04-25 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
KR101800595B1 (ko) 2008-08-27 2017-11-22 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한, ｓ1ｐ1 수용체 효능제로서의 치환된 트리시클릭 산 유도체
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
EP2364088B1 (en) * 2008-10-30 2014-04-16 Biogen Idec MA Inc. Bicyclic aryl sphingosine 1-phosphate analogs
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN102884064B (zh) 2010-03-03 2016-01-13 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
EP2455081A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
KR101787543B1 (ko) 2014-08-22 2017-10-19 샘표식품 주식회사 발효배양 산삼을 포함하는 항염증 조성물
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN112512516A (zh) 2018-07-27 2021-03-16 普瑞奥治疗有限公司 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂
EP3847158A1 (en) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US5447922A (en) 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
CN1137086C (zh) 1997-04-04 2004-02-04 三菱制药株式会社 2-氨基丙烷-1,3-二醇化合物、其作为医药的用途及其合成中间体
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
WO2000001388A1 (fr) 1998-07-02 2000-01-13 Kyowa Hakko Kogyo Co., Ltd. Medicaments antidiabetiques
AU767241B2 (en) 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
US20020143034A1 (en) 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
WO2001098301A1 (fr) 2000-06-20 2001-12-27 Japan Tobacco Inc. Composes de pyrazolopyridine et utilisation de ces derniers en tant que medicaments
IL153594A0 (en) 2000-07-13 2003-07-06 Sankyo Co Amino alcohol derivatives and pharmaceutical compositions containing the same
JP2002053575A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd アミノアルコ−ル類
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
CA2437358A1 (en) 2001-01-30 2002-08-22 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
ATE447970T1 (de) 2001-02-08 2009-11-15 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
BR0207434A (pt) 2001-02-22 2004-07-06 Novartis Ag Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos
DK1377593T3 (da) 2001-03-26 2006-04-10 Novartis Ag 2-Amino-propanolderivater
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ES2316613T3 (es) 2001-05-10 2009-04-16 Ono Pharmaceutical Co., Ltd. Derivados de acido crboxilico y composiciones farmaceuticas que contienen los mismos como ingrediente activo.
JP2004534772A (ja) 2001-05-24 2004-11-18 藤沢薬品工業株式会社 アミノアルコール誘導体
WO2003020313A1 (fr) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
MXPA04002679A (es) * 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
JP2003267936A (ja) 2002-01-11 2003-09-25 Sankyo Co Ltd ベンゼン環化合物
CA2473461C (en) 2002-01-11 2011-11-01 Sankyo Company, Limited Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
AU2003218056A1 (en) 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
ES2464157T3 (es) 2002-06-26 2014-05-30 Ono Pharmaceutical Co., Ltd. Remedios para enfermedades causadas por contracción o dilatación vascular
EP1546110A4 (en) 2002-07-30 2008-03-26 Univ Virginia ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE
BR0314113A (pt) 2002-09-13 2005-07-12 Novartis Ag Derivados de amino propanol
CA2498944C (en) 2002-09-19 2011-05-17 Yasushi Kohno Amino alcohol derivatives, salts thereof and immunosuppressive agents
WO2004028521A2 (en) 2002-09-24 2004-04-08 Novartis Ag Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
JP4140698B2 (ja) 2002-10-18 2008-08-27 第一三共株式会社 リン酸又はホスホン酸誘導体
CA2509218C (en) 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
MXPA05008531A (es) 2003-02-11 2005-11-17 Irm Llc Compuestos biciclicos novedosos y composiciones.
MXPA05008760A (es) 2003-02-18 2006-03-21 Kyorin Seiyaku Kk Derivados de acido aminofosfonico, sales del mismo y moduladores del receptor sip.
CA2707750A1 (en) * 2003-04-08 2004-10-21 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
JP2004307442A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ヘテロ環誘導体とその付加塩及び免疫抑制剤
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
JP2004307441A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ベンゼン誘導体とその付加塩及び免疫抑制剤
JP2004307439A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd アミノジオール誘導体とその付加塩及び免疫抑制剤
JP4638410B2 (ja) 2003-04-30 2011-02-23 ノバルティス アーゲー スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体
WO2004096752A1 (en) 2003-04-30 2004-11-11 Novartis Ag Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
WO2004103279A2 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
CA2524054C (en) 2003-05-19 2012-04-24 Irm Llc Immunosuppressant compounds and compositions
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
JP2005047899A (ja) 2003-07-11 2005-02-24 Sankyo Co Ltd アミノアルコール化合物
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
WO2005014603A1 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Phosphinane compounds with immunomodulating activity
CN1874996B (zh) 2003-08-28 2011-05-18 诺瓦提斯公司 氨基丙醇衍生物
CN101407471A (zh) 2003-08-29 2009-04-15 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
WO2005032465A2 (en) 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
GB0324210D0 (en) 2003-10-15 2003-11-19 Novartis Ag Organic compounds
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200526548A (en) 2003-12-25 2005-08-16 Sankyo Co Ether derivatives
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
AU2005217641B2 (en) 2004-02-24 2008-02-14 Irm Llc Immunosuppressant compounds and compositions
US7910617B2 (en) 2004-02-24 2011-03-22 Sankyo Company, Limited Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
JP2005247691A (ja) 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
SI1740217T1 (sl) * 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
EP1755680A1 (en) * 2004-05-03 2007-02-28 Novartis AG Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
GB0411929D0 (en) 2004-05-27 2004-06-30 Novartis Ag Organic compounds
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
KR101178318B1 (ko) 2004-07-16 2012-08-29 교린 세이야꾸 가부시키 가이샤 효과적인 의약의 사용법 및 부작용 발현의 방어에 관한방법
TW200611687A (en) 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
BRPI0514316A (pt) 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
PL2511262T3 (pl) 2004-10-12 2017-08-31 Kyorin Pharmaceutical Co., Ltd. Sposób wytwarzania chlorowodorku 2-amino-2-[2-[4-(3-benzyloksyfenylotio)-2-chlorofenylo]etylo]-1,3-propanodiolu
JPWO2006041015A1 (ja) 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
JP2008522977A (ja) 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
TW200702326A (en) 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
DK1926483T3 (da) 2005-09-09 2011-03-14 Novartis Ag Behandling af autoimmune sygdomme
BRPI0617077A2 (pt) 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
US8546452B2 (en) 2005-10-12 2013-10-01 Toa Eiyo Ltd. S1P3 receptor antagonist
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
MX2009000907A (es) 2006-07-25 2009-02-04 Alcon Res Ltd Antagonistas de los receptores de la subfamilia 3 del gen de diferenciacion endotelial (edg-3, sip3) para la prevencion y tratamiento de trastornos oculares.
US7877152B2 (en) 2006-07-31 2011-01-25 JusJas LLC Bipolar stimulation/recording device with widely spaced electrodes

Also Published As

Publication number Publication date
NO20082708L (no) 2008-09-02
CY1116112T1 (el) 2017-02-08
TW200806281A (en) 2008-02-01
AU2007213194B9 (en) 2013-05-16
MY151193A (en) 2014-04-30
PL1982708T3 (pl) 2015-03-31
EP1982708B1 (en) 2014-11-05
TWI389683B (zh) 2013-03-21
US8318811B2 (en) 2012-11-27
RU2428976C2 (ru) 2011-09-20
MA31338B1 (fr) 2010-05-03
EP1982708A4 (en) 2010-03-17
ES2524056T3 (es) 2014-12-03
US20090137685A1 (en) 2009-05-28
PT1982708E (pt) 2014-12-23
AU2007213194B2 (en) 2013-03-14
NZ568907A (en) 2011-08-26
EP1982708A1 (en) 2008-10-22
SG169370A1 (en) 2011-03-30
KR20080096650A (ko) 2008-10-31
WO2007091501A1 (ja) 2007-08-16
IL192150A (en) 2015-04-30
BRPI0706971A2 (pt) 2011-09-27
ECSP088662A (es) 2008-09-29
EP2520291A1 (en) 2012-11-07
TNSN08246A1 (en) 2009-10-30
DK1982708T3 (en) 2014-12-01
JPWO2007091501A1 (ja) 2009-07-02
SI1982708T1 (sl) 2015-01-30
HRP20080421A2 (en) 2008-12-31
MX2008008872A (es) 2008-10-23
JP5042042B2 (ja) 2012-10-03
RU2008135264A (ru) 2010-03-20
HRP20080421B1 (hr) 2015-07-17
ZA200806199B (en) 2009-04-29
GT200800148A (es) 2008-10-29
CN101378743B (zh) 2014-05-28
AU2007213194A1 (en) 2007-08-16
CA2641546C (en) 2013-12-24
CN101378743A (zh) 2009-03-04
IL192150A0 (en) 2008-12-29
CA2641546A1 (en) 2007-08-16
KR101334153B1 (ko) 2013-11-28

Similar Documents

Publication Publication Date Title
HK1126119A1 (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13-
IL209121A (en) Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases
IL206296A (en) History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases
IL193678A (en) Derivatives of pyrazolyl-theophane, pharmaceuticals containing them and their use in the preparation of drugs to improve cognitive activity
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
IL216741A (en) History of imidazolidine-2-van 1,3-imaging modalities as 17-cyp inhibitors, pharmaceutical preparations containing them, and their use in the preparation of drugs for the treatment of diseases
HK1129106A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
IL218674A (en) Compounds that inhibit lrrk2 kinase activity, pharmacological preparations containing them, and their use in the preparation of Parkinson's disease drugs
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP1848270A4 (en) TRANSMUCOSAL ADMINISTRATION OF MEDICINAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF DISEASES IN ANIMALS
EP2093237A4 (en) ANTICANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
IL209282A (en) History of n-pipridine-3-yl-2-benzimidazole carboxamide and drugs containing it for the treatment of cardiovascular disease
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
IL201189A (en) Fluorization derivatifrone derivatives used as iron pellets in the treatment of neurodegenerative diseases, their preparation and their pharmaceutical preparations
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
IL204741A (en) Ceramide History for the Treatment of Multiple Cyst Diseases and Pharmaceuticals Containing These History
IL197575A (en) A method for removing adult stem cells from the blood, using them to prepare drugs for the treatment of lesions, and a medical preparation containing these adult GES cells
IL194880A (en) Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them
EP2142549A4 (en) ADENOSINE DERIVATIVES, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES THEREOF CONTAINING THEM AS AN ACTIVE SUBSTANCE
IL215840A (en) Arylsulfonamide compounds are converted into two positions 2 and 5, their pharmaceutical composition containing them and their use in the treatment of ccr3-related diseases
IL196606A (en) Use of Eskin for the preparation of medical preparations and medical preparations containing Eskin for the treatment of diseases
EP1954800A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
EP1928247A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
EP2231148A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190208